Login

NON-SUBSCRIBER OPTIONS
FREE TRIAL   |   NEWSSTAND

Home

Top Story

CMS: Doc Participation In Cancer Care Model Nearly Double Expectations

CMS on Wednesday (June 29) announced that nearly twice the expected number of physician practices joined the Oncology Care Model -- though an Avalere analysis notes none will participate in 19 states.

Latest News

FDA tapped the director of the Office of Hematology and Oncology Products, Richard Pazdur, to head the agency’s new Oncology Center of Excellence that will focus on uniting cancer product regulatory review and leverage clinical expertise across FDA as part of the vice president’s Cancer Moonshot Initiative.

Federal lawyers told the U.S. District Court in Iowa that CoOportunity's attempt to stop HHS from redirecting money the company needs to pay off claims would hurt other insurers in the state if HHS does not put the funds toward risk adjustment payments, according to a U.S. Department of Justice brief filed June 24.

A Medicaid beneficiary advocate told Inside Health Policy the program’s current supplemental payment systems may need to be improved, but it is crucial the provider safety-net remain intact in the process.

FDA released draft guidance outlining its expectations and recommendations for the evaluation and reporting of age, race and ethnicity data in medical device clinical studies.

HHS wants to let government attorneys make certain decisions at the third level of appeals and to allow the Departmental Appeals Board to designate certain decisions as precedents.

Health IT Now wrote to House and Senate leaders and conferees urging them to include language in the final opioid bill calling for states to put in place standards ensuring interoperable Prescription Drug Monitoring Programs.

The Obama administration has finally shown how it intends to respond to the growing number of lawsuits over the Affordable Care Act’s risk corridor funding gap.

The U.S Pharmacopeial Convention defended the role of mandatory USP drug quality standards in biosimilar development as FDA and Senate lawmakers seek to remove biologics from such monographs.